Post-Hoc Analysis of ATTAIN Trials Shows Orforglipron Produces 14% Weight Loss Independent of Menopausal Status
Post-hoc analysis of two Eli Lilly-sponsored RCTs indicates oral orforglipron achieves clinically meaningful weight loss regardless of menopausal status. Absolute reductions reached 14% body weight and 12.5 cm waist circumference at 72 weeks. Evidence quality is moderate: randomized but subgroup-derived, industry-affiliated, and lacking long-term hard-outcome data.
The analysis pooled 142-225 women per menopausal stratum from two randomized, placebo-controlled trials. ATTAIN-1 enrolled participants with overweight or obesity without diabetes; ATTAIN-2 required type 2 diabetes. Participants received orforglipron or placebo for 72 weeks; primary endpoints were percent weight change and proportions achieving 5-20% loss thresholds. Waist-to-height ratio and absolute waist circumference were prespecified secondary measures.
Results showed consistent relative weight loss (up to 14%) and visceral-fat proxy reductions across strata, suggesting GLP-1 receptor agonism bypasses estrogen-related shifts in energy expenditure and fat distribution. However, the data derive from a manufacturer-affiliated post-hoc subgroup analysis without formal interaction testing or adjustment for multiple comparisons, limiting causal claims about menopausal status.
Broader context includes rising demand for oral GLP-1 agents amid injectable supply constraints and known adherence barriers for postmenopausal women managing central adiposity. Comparable efficacy was observed with injectable semaglutide in the STEP trials, yet head-to-head data remain absent. Next, fully powered phase 3 cardiovascular-outcome trials must report sex- and menopause-stratified endpoints to confirm durability and safety beyond 72 weeks.
VITALIS: Lilly's phase 3 CVOT will report <10% discontinuation due to GI events in the postmenopausal arm at 104 weeks, or the indication will be narrowed.
Sources (3)
- [1]ATTAIN-1 and ATTAIN-2 Trial Results(https://clinicaltrials.gov/ct2/show/NCT05803421)
- [2]STEP 1 Trial Semaglutide Menopause Subgroup(https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)
- [3]Meta-analysis of GLP-1 Efficacy by Sex(https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00145-6/fulltext)